Glutamine News and Research

RSS

Glutamine is an amino acid used in nutrition therapy. It is also being studied for the treatment of diarrhea caused by radiation therapy to the pelvis.

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain bladder cancers and mesotheliomas have metabolic changes and are more likely to respond to treatment with ADI-PEG 20 (pegylated arginine deiminase) if they are deficient in the enzyme, argininosuccinate synthetase.

18 Apr 2013

Science behind medical acupuncture

A special issue of Medical Acupuncture presents a series of articles by authors from around the world who provide diverse and insightful perspectives on the science and physiologic responses underlying medical acupuncture.

17 Apr 2013

Pancreatic cancer cells' growth are fueled by metabolic pathway, scientists find

Dana-Farber Cancer Institute scientists and colleagues have discovered that pancreatic cancer cells' growth and spread are fueled by an unusual metabolic pathway that someday might be blocked with targeted drugs to control the deadly cancer.

28 Mar 2013

MID1 complex binds with messenger RNA and controls synthesis of defective Huntingtin

Huntington's disease, also known as Huntington's chorea, is a hereditary brain disease causing movement disorders and dementia. In Germany, there are about 8,000 patients affected by Huntington's disease, with several hundred new cases arising every year. The disease usually manifests between the ages of 35 and 50.

27 Feb 2013

PKCζ protein plays a critical role in regulating tumor metabolism

Cancer cells need food to survive and grow. They're very good at getting it, too, even when nutrients are scarce. Many scientists have tried killing cancer cells by taking away their favorite food, a sugar called glucose. Unfortunately, this treatment approach not only fails to work, it backfires-glucose-starved tumors actually get more aggressive.

2 Feb 2013

Fifteen established scientists to receive NARSAD Distinguished Investigator Grants

The Brain & Behavior Research Foundation (formerly NARSAD, the National Alliance for Research on Schizophrenia and Depression) announced the latest recipients of its highly competitive NARSAD Distinguished Investigator Grants.

16 Jan 2013

Researchers uncover mechanism that switches off cell transport regulating proteins

Researchers at the RUB and from the MPI Dortmund have uncovered the mechanism that switches off the cell transport regulating proteins. They were able to resolve in detail how the central switch protein Rab is down-regulated with two "protein fingers" by its interaction partners.

20 Dec 2012

Sickle cell disease trial completes phase 3 patient enrollment

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced the completion of patient enrollment for its phase 3 clinical trial to study L-glutamine as a treatment for sickle cell disease.

5 Dec 2012

Researchers find that children's brains are more affected by inhaled anesthetic

Stony Brook University School of Medicine researchers have found that children's brains are more affected by an inhaled anesthetic than an intravenous anesthetic with increased levels of brain lactate.

29 Oct 2012

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

Sickle cell disease is a devastating hereditary condition that affects millions of people, particularly those in West and Central Africa as well as people of African descent in the United States, Europe and South America.

23 Oct 2012

Researchers identify 21 proteins that specifically bind to ataxin-1

Misfolded proteins can cause various neurodegenerative diseases such as spinocerebellar ataxias (SCAs) or Huntington's disease, which are characterized by a progressive loss of neurons in the brain. Researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, together with their colleagues of the Universit- Paris Diderot, Paris, France, have now identified 21 proteins that specifically bind to a protein called ataxin-1.

19 Sep 2012

Emmaus Medical to complete target enrollment in L-Glutamine Phase III trial for sickle cell disease

In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.

14 Sep 2012

Wellness Center USA closes PSI acquisition

Wellness Center USA, Inc., a Schaumburg IL based healthcare and nutraceutical company, reported the closing of its Psoria-Shield Inc. (PSI) acquisition. PSI is a Tampa, FL based developer and manufacturer of UltraViolet (UV) phototherapy devices for the treatment of skin diseases.

29 Aug 2012

Glutamatergic system involvement in BD supported

Results from a systematic review and meta-analysis of published studies suggest that brain levels of glutamate plus glutamine are elevated in bipolar disorder patients compared with mentally healthy individuals.

2 Aug 2012

Allergy to deamidated gluten a separate phenotype to wheat allergy

Severe allergic reactions to deamidated gluten in individuals tolerant to wheat are linked to a separate phenotype of wheat allergy, suggest study findings.

20 Jul 2012

Emmaus receives EC Orphan Medicinal Product designation for Levoglutamide

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission (EC) has granted Orphan Medicinal Product designation for the company's investigational drug Levoglutamide (L-glutamine) for the treatment of sickle cell disease.

18 Jul 2012

Treating Sickle Cell Disease with L-Glutamine

By focusing on how best to help patients, researchers can sometimes find solutions that are much simpler than anticipated. That has been the guiding approach to our efforts to develop a treatment for sickle cell disease.

3 Jul 2012

New research into cell-damaging effects of Huntington's disease

New research into the cell-damaging effects of Huntington's disease suggests a potentially new approach for identifying possible therapeutic targets for treating the nerve-destroying disorder.

7 Jun 2012

New treatment for sickle cell disease developed by Emmaus Medical receives positive opinion from EMA

Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.

30 May 2012

Study shows how a drug-lead compound suppresses tumour formation

A team of scientists from the National University of Singapore's (NUS) Department of Biological Sciences and Mechanobiology Institute have discovered how a drug-led compound - a compound that is undergoing preclinical trials as a potential drug - can deprive cancer cells of energy and stop them from growing into a tumour. This drug-led compound is named BPTES.

21 May 2012